Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

UCB Major Shareholding Notification 2016

Sep 8, 2016

4017_mrq_2016-09-08_cc2d11ac-72df-4f3b-8035-239cb4a07c25.pdf

Major Shareholding Notification

Open in viewer

Opens in your device viewer

{# SEO P0-1: filing HTML is rendered server-side so Googlebot sees the full text without executing JS or following an iframe to a Disallow'd CDN path. The content has already been sanitized through filings.seo.sanitize_filing_html. #}

Transparency notifications

Brussels (Belgium), 8 September 2016 – 20:00 (CEST) – regulated information

1. Summary of the notifications

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received 2 transparency notifications from Wellington Management Group LLP (having its registered offices at 280 Congress Street, Boston, MA 02110, USA), dated 5 and 6 September 2016 respectively.

In the first notification, Wellington Management Group LLP informed that, following a disposal of UCB shares with voting rights by its affiliates, its shareholding in UCB SA/NV had decreased and had crossed downward the 3% threshold on 1 September 2016. In the second notification, Wellington Management Group LLP notified that it crossed the 3% minimum threshold again, following an acquisition of UCB shares with voting rights by its affiliates on 2 September 2016.

On 1 September 2016, Wellington Management Group LLP (taking into account the holding of its affiliates) owned 5 811 663 UCB shares with voting rights (versus 5 872 320 UCB shares in its previous notification on 12 August 2016), representing 2.99% of the total number of shares issued by the company (194 505 658) (3.02% on 12 August 2016).

On 2 September 2016, Wellington Management Group LLP (taking into account the holding of its affiliates) announced that it owned 5 839 746 UCB shares with voting rights, representing 3.00% of the total number of shares issued by the company.

2. Content of the notifications

The transparency notification dated 5 September 2016 included the following information:

  • Reason for the notification:
  • Acquisition or disposal of voting securities or voting rights;
  • Downward crossing of the lowest threshold.
  • Date on which the threshold is crossed: 1 September 2016.
  • Threshold crossed (in %): 3%.

Notified details:

A) Voting rights Previous notification After the transaction
# of voting rights # of voting rights % of voting rights
Holders of voting rights Linked to securities Not linked to the
securities
Linked to
securities
Not linked to the
securities
Wellington Management Group LLP 0 0 0,00%
Wellington Management Company
LLP
4.768.319 4.714.394 2,42%
Wellington Management International
Ltd
1.104.001 1.097.269 0,56%
subtotal 5.872.320 5.811.663
TOTAL 5.811.663 0 2,99% 0,00%
TOTAL (Voting rights & Equivalent financial
instruments)
# of voting rights % of voting rights
CALCULATE 5.811.663 2,99%

The transparency notification dated 6 September 2016 included the following information:

  • Reason for the notification: Acquisition or disposal of voting securities or voting rights.
  • Date on which the threshold is crossed: 2 September 2016.
  • Threshold crossed (in %): 3%.
  • Notified details:
A) Voting rights Previous notification After the transaction
# of voting rights # of voting rights % of voting rights
Holders of voting rights Linked to securities Not linked to the
securities
Linked to
securities
Not linked to the
securities
Wellington Management Group LLP 0 0 0,00%
Wellington Management Company 4.714.394 4.748.356 2,44%
LLP
Wellington Management International
1.097.269 1.091.390 0,56%
Ltd
subtotal
5.811.663 5.839.746 3,00%
TOTAL 5.839.746 0 3,00% 0,00%
TOTAL (Voting rights & Equivalent financial
instruments)
# of voting rights % of voting rights
CALCULATE 5.839.746 3,00%

The information mentioned hereafter was identical in both notifications:

  • Notification by: A parent undertaking or a controlling person.
  • Person subject to the notification requirement: Wellington Management Group LLP, 280 Congress Street, Boston, MA 02110, USA
  • Denominator: 194 505 658.

Chain of controlled undertakings through which the holding is effectively held:

Wellington Management Company LLP is a direct controlled undertaking of Wellington Investment Advisors Holdings LLP, which, in turn, is a direct controlled undertaking of Wellington Group Holdings LLP, which, in turn, is a direct controlled undertaking of Wellington Management Group LLP.

Wellington Management International Ltd, is a direct controlled undertaking of Wellington Management Global Holdings, Ltd, which, in turn, is a direct controlled undertaking of Wellington Investment Advisors Holdings LLP, which, in turn, is a direct controlled undertaking of Wellington Group Holdings LLP, which, in turn, is a direct controlled undertaking of Wellington Management Group LLP.

Additional information:

Wellington Management Company LLP is an investment management company and can exercise the voting rights at its discretion in the absence of specific instructions from the beneficial owners of the shares.

Wellington Management International Ltd is an investment management company and can exercise the voting rights at its discretion in the absence of specific instructions from the beneficial owners of the shares.

3. Further information

This press release and the detailed transparency notifications are available on UCB SA/NV's website via the following link.

An updated overview of the UCB SA/NV large shareholdings will be included in the corporate governance charter of UCB SA/NV, which is available on its website via the following link.

Investor Relations

Antje Witte, Investor Relations, UCB T +32 2 559 94 14, [email protected]

Isabelle Ghellynck, Investor Relations, UCB T +32 2 559 95 88, [email protected]

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7 500 people in approximately 40 countries, the company generated revenue of € 3.9 billion in 2015. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news